#### MOMENTA PHARMACEUTICALS INC

Form SC 13G/A January 26, 2006

CUSIP No. 60877T 10 1

Page 1 of 8 Pages

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILES PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 1)[1]

Momenta Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$.0001 par value

(Title of Class of Securities)

60877T 10 1

December 31, 2005

Date of Event Which Requires Filing of this Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is Filed:

[ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ X ] Rule 13d-1(d)

\_\_\_\_\_

[1] The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 60877T 10 1

Page 2 of 8 Pages

1) Name of Reporting Person MVM International Life
I.R.S. Identification Sciences Fund No. 1, L.P.
No. of Above Person
(Entities Only)

2) Check the Appropriate Box

(a) [ X ]

3)	SEC Use Only					
 4)	Citizenship or Place of Organization	United Kingdom				
Number of Shares Beneficially Owned by Each Reporting Person With		5)	Sole Voting Power		-0-	
		6)	Shared Votin	 ng	1,610,850	
		7)	Sole Dispos: tive Power	i-	-0-	
		8)	Shared Dis- positive Por		1,610,850	
9)	Aggregate Amount Beneficially Owned by Each Reporting person				1,610,850 of Common	
10)	Check if the Aggregate Amount in Row (9) Excludes Certain Share					
11)	Percent of Class Represented by Amount in Row (9)				5.3%	
12)	Type of Reporting Person				PN	
			-2-			
CUSI	P No. 60877T 10 1					Page 3 of 9 Page
 1)	Name of Reporting Pers I.R.S. Identification No. of Above Person (Entities Only)	on		MVM Life Partners		
	Check the Appropriate if a Member of a Group	)		(a) [ X ] (b) [ ]		
	SEC Use Only					
 4)	Citizenship or Place of Organization			United Ki	ingdom	
Shar Owne	er of es Beneficially d by Each rting Person	5)	Sole Voting Power		-0-	

				8,656 shares of Common Stock	
		7)	Sole Disposi- tive Power	-0-	
			Shared Dis- positive Power		
9)	Aggregate Amount Beneficially Owned by Each Reporting person			8,656 shares of Common Stock	
10)	Check if the Aggregate Amount in Row (9) Excludes Certain Share	: :S			
11)	Percent of Class Represented by Amount in Row (9)			less than 0.1%	
12)	Type of Reporting Person			00	
			-3-		

-3-

CUSIP No. 60877T 10 1

Page 4 of 8 Pages

Amendment No. 1 to Schedule 13G

Reference is hereby made to the statement on Schedule 13G originally filed with the Securities and Exchange Commission on January 27, 2005 (the "Schedule 13G".) Terms defined in the Schedule 13G are used herein as so defined.

The following Items of the Schedule 13G are hereby amended and restated to read in their entirety as follows:

Item 2(a) - Name of Person Filing:

> MVM International Life Sciences Fund No. 1, L.P. ("MVM Fund No. 1")

MVM Life Science Partners LLP ("MVM")

Item 4 - Ownership.

(a) Amount Beneficially Owned:

MVM Fund No. 1: 1,610,850 shares of Common Stock MVM: 8,656 shares of Common Stock

(b) Percent of Class:

MVM Fund No. 1: 5.3% MVM: less than 0.1%

(c) Number of shares as to which such person has:

- (i) sole power to vote or to direct the vote: -0-
- (ii) shared power to vote or to direct the vote:

MVM Fund No. 1: 1,610,850 shares of Common Stock MVM: 8,656 shares of Common Stock

- (iii) sole power to dispose or to direct the disposition of: -0-
- (iv) shared power to dispose or to direct the disposition of:

MVM Fund No. 1: 1,610,850 shares of Common Stock MVM: 8,656 shares of Common Stock

-4-

CUSIP No. 60877T 10 1

Page 5 of 8 Pages

Item 8 - Identification and Classification of Members of the Group:

See Exhibit 2.

-5-

CUSIP No. 60877T 10 1

Page 6 of 8 Pages

Signature:

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

MVM INTERNATIONAL LIFE SCIENCES FUND NO. 1, L.P.

By /s/ Thomas Casdagli
----Director of Finance

MVM LIFE SCIENCE PARTNERS LLP

By /s/ Thomas Casdagli ----Member

Date: January 17, 2006

CUSIP No. 60877T 10 1

Page 7 of 8 Pages

EXHIBIT 1

AGREEMENT OF

MVM INTERNATIONAL LIFE SCIENCES

FUND NO. 1, L.P.

AND MVM LIFE SCIENCE PARTNERS LLP

PURSUANT TO RULE 13d-1(f)

The undersigned hereby agree that the Information Statement on Schedule 13G to which this Agreement is annexed as Exhibit 1 is filed on behalf of each of them in accordance with provisions of 13d-1(f) under the Securities Exchange Act of 1934, as amended.

MVM INTERNATIONAL LIFE SCIENCES FUND NO. 1, L.P.

By /s/ Thomas Casdagli
----Director of Finance

MVM LIFE SCIENCE PARTNERS LLP

By /s/ Thomas Casdagli
----Member

Date: January 17, 2006

-7-

CUSIP No. 60877T 10 1

Page 8 of 8 Pages

EXHIBIT 2

Identification and Classification of Members of the Group

MVM International Life Sciences Fund No. 1, L.P. and MVM Life Science Partners LLP are filing this statement on Schedule 13G as a group.

MVM International Life Sciences Fund No. 1, L.P. is a United Kingdom limited partnership. MVM Life Science Partners LLP is a limited liability partnership organized in the United Kingdom. MVM Life Science Partners LLP is the discretionary investment manager of MVM International Life Sciences Fund No. 1, L.P.